Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H17N2O3.Na |
Molecular Weight | 248.254 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC1(CCC(C)C)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=BNHGKKNINBGEQL-UHFFFAOYSA-M
InChI=1S/C11H18N2O3.Na/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1
Molecular Formula | C11H18N2O3 |
Molecular Weight | 226.2722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/ppa/amobarbital-sodium.html
Sources: https://www.drugs.com/ppa/amobarbital-sodium.html
AMOBARBITAL is a barbiturate derivative with hypnotic and sedative properties. In an in vitro study in rat thalamic slices amobarbital worked by activating GABAA receptors, which decreased input resistance, depressed burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increased both the amplitude and decay time of inhibitory postsynaptic currents. Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6099281 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Amytal Sodium Approved UseUnknown |
|||
Primary | Amytal Sodium Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The alcoholic metabolites of pentobarbital and amobarbital in man. | 1965 Oct |
|
Dystonic reactions to prochlorperazine in hypoparathyroidism. | 1966 Nov 3 |
|
Hypomagnesemia with convulsions in a newborn infant. Report of a case associated with maternal hypophosphatemia. | 1967 Sep 30 |
|
Hypotensive effects of chlordiazepoxide, amobarbital and chlorpromazine on behaviorally induced elevated arterial blood pressure in the squirrel monkey. | 1970 Jun |
|
Amobarbital metabolism in man: N-glucoside formation. | 1978 Jul |
|
Seven cases of somnambulism induced by drugs. | 1979 Jul |
|
Respiratory failure after clonazepam and amobarbital. | 1986 Nov |
|
High-performance liquid chromatographic determination of the diastereomers of 1-(beta-D-glucopyranosyl)amobarbital in urine. | 1987 Nov 27 |
|
Regulation of hepatic nitric oxide synthase by reactive oxygen intermediates and glutathione. | 1995 Feb 1 |
|
Clinical experimental observations of carotid artery injections of sodium amytal. | 1997 Feb |
|
Transcortical mixed aphasia due to cerebral infarction in left inferior frontal lobe and temporo-parietal lobe. | 2002 Feb |
|
Evidence that a type-2 NADH:quinone oxidoreductase mediates electron transfer to particulate methane monooxygenase in methylococcus capsulatus. | 2002 Feb 1 |
|
Effect of the new matrix metalloproteinase inhibitor RO-28-2653 on mitochondrial function. | 2002 Feb 15 |
|
[Rotenone-insensitive NADH oxydation in mitochondrial suspension occurs by NADH dehydrogenase of respiratory chain fragments]. | 2004 Sep-Oct |
|
Role of endothelial mitochondria in oxidant production and modulation of neutrophil adherence. | 2004 Sep-Oct |
|
Electron transport pathways for the oxidation of endogenous substrate(s) in Acidithiobacillus ferrooxidans. | 2006 Apr |
|
Amygdalohippocampal involvement in tinnitus and auditory memory. | 2006 Dec |
|
Amytal interview using intravenous lorazepam in a patient with dissociative fugue. | 2006 Nov-Dec |
|
Comorbid substance-use in schizophrenia: the file drawer effect, In reply to: Talamo et al., 2006. "Comorbid substance-use in schizophrenia: relation to positive and negative symptoms". | 2007 Feb |
|
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease? | 2009 Dec |
|
Acquired and congenital disorders of sung performance: A review. | 2009 Nov 12 |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Transitional Nerve: A New and Original Classification of a Peripheral Nerve Supported by the Nature of the Accessory Nerve (CN XI). | 2010 |
|
Temporary test occlusion of distal middle cerebral artery using GDC coil. | 2010 Apr |
|
Mutism as the presenting symptom: three case reports and selective review of literature. | 2010 Jan |
|
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010 Mar 3 |
|
Multiple myeloma presenting as CEA-producing rectal cancer. | 2010 Mar 31 |
|
Identification of a novel phosphorylation site in hepatitis C virus NS5A. | 2010 Oct |
|
Prozone effect of serum IgE levels in a case of plasma cell leukemia. | 2010 Sep 10 |
|
[The use of enzymatic hydrolysis for isolation of barbituric acid derivatives from blood (as exemplified by phenobarbital and barbamyl)]. | 2010 Sep-Oct |
Patents
Sample Use Guides
Sedative: 30 to 50 mg given 2 or 3 times daily.
Hypnotic: 65 to 200 mg at bedtime.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6099281
To 100mkl of the tissue homogenate were added 50 mkl of [3SS]TBPS (at the appropriate concentration, and made in 1 M NaBr), 50 mkl of 50 mM Tris Citrate buffer (to define total binding) or AMOBARBITAL at 100mkM or 50mkl of 40mkM picrotoxinin (to define nonspecific binding). The mixture was incubated 90 min at 21°C and then filtered over glass-fiber filters (Schleicher and Schuell No. 32). Filters were washed three times with 5 ml 0.9% (w:v) NaC1 equilibrated to 21°C and then counted by liquid scintillation spectrometry.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:13 UTC 2023
by
admin
on
Fri Dec 15 15:34:13 UTC 2023
|
Record UNII |
G0313KNC7D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2125
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1314242
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | RxNorm | ||
|
G0313KNC7D
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
64-43-7
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
200-584-9
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
C76524
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
DTXSID40213975
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
m1837
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000085178
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
CHEMBL267894
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
SUB00498MIG
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
G0313KNC7D
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
13389383
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY | |||
|
DBSALT001490
Created by
admin on Fri Dec 15 15:34:13 UTC 2023 , Edited by admin on Fri Dec 15 15:34:13 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |